ZXZheng-Min Xu

Zheng-Min Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zheng-Min Xu has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Yue Huang

    Department of Otolaryngology-Head and Neck Surgery, Children’s Hospital of Fudan University , No 399 Wanyuan Road , Shanghai , China

    11 shared publications
  • Bo Duan

    Department of Otolaryngology-Head and Neck Surgery, Children’s Hospital of Fudan University , No 399 Wanyuan Road , Shanghai , China

    8 shared publications
  • Wen-Xia Chen

    Department of Otolaryngology—Head and Neck Surgery, Children’s Hospital of Fudan University, Shanghai, China

    8 shared publications
  • Ping Lu

    Fudan Univ, Childrens Hosp, Dept Otolaryngol Head & Neck Surg, 399 Wan Yuan Rd, Shanghai 201102, Peoples R China

    7 shared publications
  • Wenxia Chen

    Department of Otolaryngology-Head and Neck Surgery, Children’s Hospital of Fudan University, Shanghai, China

    7 shared publications
  • Chao Chen

    Department of Otolaryngology Head and Neck Surgery,Children's Hospital of Fudan University,Shanghai,201102,China

    6 shared publications

Latest Publications

  • Open Access

    Autoinflation for the Treatment of Persistent Otitis Media With Effusion in Children

    by Shuixia Liu, Wenxia Chen, Yong Zhang, Zhengmin Xu, Yue Huang

    Importance: Otitis media with effusion (OME) is common in children, often persisting for more than 3 months, which can lead to hearing loss. Effective treatments are needed to manage this condition. Objective: To evaluate the efficacy and safety of autoinflation for persistent OME in children. Design: Retrospective cohort study. Setting: The study was conducted at a tertiary pediatric hospital. Participants: A total of 131 children with persistent OME were enrolled from January 2020 to July 2025. Seventy-one children received autoinflation treatment, and 60 children were assigned to the control group. Exposure or Intervention: The autoinflation group received twice-daily autoinflation treatment for 1 to 3 months in addition to medical therapy. The control group received only medical therapy. Main Outcome Measures: Efficacy was evaluated based on cure rates assessed by tympanometry and otoacoustic emissions before and after treatment. Safety was assessed through the frequency and severity of adverse events. Results: In the autoinflation group after 3 months, 60.8% of ears were cured, and 13.3% showed improvement. In the control group, only 20.0% of ears were cured, and 20.0% improved. Univariate analysis indicated that recurrent OME and recurrent/prolonged respiratory tract infections were significant risk factors for autoinflation failure. Approximately half of the children experienced mild ear pain during the first week, which was generally tolerable. Conclusion: Autoinflation appears to be safe and effective in children with persistent OME. Treatment failure is more common in children with recurrent/prolonged respiratory infections or recurrent OME, especially in those with a history of middle ear surgery (adenoidectomy with tympanostomy tube insertion). Although autoinflation is a low-risk alternative to surgery for suitable patients, it should be avoided in children with skull base or orbital defects, craniofacial anomalies, or active infection or inflammation. Relevance: This retrospective cohort study supports the use of autoinflation as a treatment option for persistent OME. Identifying risk factors for treatment failure may help guide clinical decisions.

  • [Expert consensus on the clinical application of oral antihistamines in the treatment of upper airway allergic diseases in children].

    by Zhengmin Xu

    Upper airway allergic disease in children refers to chronic non-infectious inflammatory diseases of the upper airway caused by allergic inflammation. These diseases have high prevalences and great harm. Attentions should be paid to the treatment of these diseases. Oral antihistamines play an important role in the treatment of allergic diseases. However, there are many types of antihistamines. How to select appropriate antihistamines according to the age and characteristics of children to treat upper airway allergic diseases is a concern of pediatricians. Therefore, the Pediatric Otorhinolaryngology and Head and Neck Surgery Committee of the Chinese Association for the Promotion of Human Health Science and Technology organized relevant experts to form this consensus, in order to guide the use of oral antihistamines in children with upper airway allergic diseases.

  • Open Access

    Inhibition of mast cell activation by Jaranol-targeted Pirin ameliorates allergic responses in mouse allergic rhinitis

    by Yue Huang, Shuhua Su, Bo Duan, Yunfei Zhang, Zhengmin Xu

    Jaranol, a bioactive compound derived from various traditional medicinal herbs, has demonstrated significant anti-inflammatory properties. This study investigates its effects and possible mechanisms underlying its anti-inflammatory role in mast cells, as well as ovalbumin (OVA)-induced allergic rhinitis (AR) mice model. Forty mice were randomly divided into blank, AR, dexamethasone (positive control), and Jaranol groups (10 mg/ml), with 10 mice in each group. Jaranol was found to inhibit nasal mucosal inflammation and reduce mast cell numbers in AR models. It also inhibited the secretion of several inflammatory cytokines (IFN-γ, TNF-α, IL-1β, IL-6, MCP-1, and CXCR10) from mast cells, as well as mast cell proliferation and migration. Interestingly, Pirin was differentially expressed in blank, AR, and Jaranol groups. Further studies indicated that Jaranol inhibited inflammatory cytokine secretion from mast cells by mediating Pirin and also inhibited mast cell proliferation and migration. Moreover, it inhibited mast cell function by suppressing Pirin expression. These findings suggest that Jaranol exerts its therapeutic effects by inhibiting Pirin expression in mast cells, thereby reducing inflammation and histopathological changes associated with AR.


  • Open Access

    One-stage thyroid cartilage laryngotracheal reconstruction for children less than one year old with congenital subglottic stenosis

    by Chao Chen, Yi-Hua Ni, Le-Tian Tan, Yue Huang, Zheng-Min Xu

    Objectives: To evaluate one-stage thyroid cartilage laryngotracheal reconstruction in children less than one year of age with congenital subglottic stenosis.Methods: Congenital subglottic stenosis children less than one year old who underwent one-stage thyroid cartilage laryngotracheal reconstruction between 2016 and 2020 in our department were retrospectively reviewed. Their clinical characteristics, treatments and prognoses were assessed.Results: Eleven congenital subglottic stenosis children (6–11 months) were included: seven with Myer–Cotton grade II, and four with Myer–Cotton grade III. Their tracheal diameters were corrected to normal size using thyroid cartilage, and they were intubated under sedation for two weeks after surgery. Moreover, all of them received anti-infection and anti-reflux therapies during hospitalisation. No breathing difficulty, aspiration, hoarseness or laryngitis was observed during the follow-up period (10–30 months), and their growth and development were age appropriate.Conclusion: The one-stage thyroid cartilage laryngotracheal reconstruction is a good treatment option for congenital subglottic stenosis children less than one year old with Myer–Cotton grade II–III.

  • 儿童喉气道疾病的诊治与展望

    by Zhengmin Xu

    此文章主要是描述对儿童喉气道疾病的诊断和治疗,其疾病包括先天性结构异常、感染及肿瘤,提供了一些新的诊治技术。根据儿童疾病的特点,阐述了儿童上气道阻塞的临床评估,以及综合性评估包括临床症状学、内镜及影像学检查。其中内镜检查可诊断儿童气道阻塞的程度,也可判断什么性质的疾病。例如喉裂患儿,初次到门诊就诊,可做纤维喉镜检查,得到初步的结果,如果要进一步明确喉裂的程度,需在全身麻醉下做气管硬镜检查,可明确诊断喉裂为Ⅰ型、Ⅱ型、Ⅲa型、Ⅲb型、Ⅳa型及Ⅳb型。对于儿童喉气道疾病的治疗,阐述的主要是两种方法:非手术治疗和手术治疗。举例喉裂患儿,Ⅰ型和部分Ⅱ型喉裂可保守治疗主要是饮食控制,以及进食时体位,手术治疗主要是在内镜下行Ⅱ型和Ⅲ型喉裂修补术。最后展望了一些新技术在诊断和治疗儿童喉气道疾病的应用。

  • 102例儿童声带结节的临床分析研究

    by Yihua Ni, Wenxia Chen, Zhengmin Xu

    探讨声带结节对于患儿生活质量的影响,比较保守治疗(嗓音卫生教育)与喉显微手术治疗的疗效及其差异性。 回顾性分析2020年1月-2022年12月间在复旦大学附属儿科医院耳鼻咽喉头颈外科门诊及住院治疗的102例声带结节患儿的临床资料,依据年龄分为学龄前组(2~5岁,58例)和学龄组(6~12岁,44例),依据治疗方案分为保守治疗组(52例)和手术治疗组(50例)。采用儿童嗓音相关生活质量量表(pediatric voice-related quality of life,pVRQOL)评估声带结节对患儿生活质量的影响以及两种治疗方案的疗效。 声带结节1级、2级、3级的pVRQOL评分分别为91.58±8.17,78.87±12.49,72.50±12.08,1级和2级、2级和3级评分比较差异均有统计学意义(P < 0.001),提示声带结节评级越高,患儿的pVRQOL评分越小;学龄组pVRQOL评分为69.83±11.11,学龄前组pVRQOL评分87.59±8.63,2组比较差异有统计学意义(P=0.042),声带结节对学龄组患儿pVRQOL评分影响较明显;保守治疗组治疗前后pVRQOL评分分别为83.99±12.66、87.26±9.58,差异有统计学意义(P=0.046);嗓音卫生教育等间接嗓音治疗能够改善患儿的pVRQOL评分,且对学龄患儿更有效(P < 0.001)。喉显微手术治疗对患儿pVRQOL评分的提升更为明显。 声带结节评级越高,对患儿生活质量影响越大;声带结节对学龄组患儿的生活质量影响大于学龄前组患儿;嗓音卫生教育等能改善患儿的生活质量,在学龄组中较明显。喉显微手术相较嗓音卫生教育等,改善患儿pVRQOL评分的效果更为显著。若家属要求改善嗓音相关的生活质量,则建议采用喉显微手术治疗声带结节。由于本研究随访期仅为术后6个月,因此喉显微手术治疗儿童声带结节的短期疗效明确,但长期疗效有待进一步研究。

  • 婴幼儿喉囊肿治疗新进展

    by Huiying Lv, Yihua Ni, Chao Chen, Wenxia Chen, Zhengmin Xu

    喉囊肿是发生于喉腔的囊性病变,婴幼儿喉囊肿较大时可引起喉喘鸣等上气道梗阻症状,甚至危及生命,需要及时手术治疗,目前临床上缺乏统一的治疗策略。本文将近年来喉囊肿的手术方式、各术式优缺点等进行总结。并建议在充分沟通评估,明确病变范围及手术优缺点后,选择囊肿穿刺术、部分囊壁切除术、根治性囊肿剥离术、经口机器人手术或开放性切除术。

  • Open Access

    Clinical Features and Outcomes of Omicron-Associated Croup in Children

    by Yue Huang, Shuhua Su, Zhengmin Xu, Wenxia Chen

    Objective: This study was aimed to describe the clinical features and outcomes of Omicron-associated croup in children. Methods: A total of 105 children aged 3-60 months (median age 11 months) with coronavirus disease 2019 (COVID-19) and cough were admitted to our hospital from December 16, 2022, to December 31, 2022. Their clinical features, treatment, and outcomes were reviewed. These children were followed up for 8 months. Results: Among the cases, 5 had complex medical histories, while the other children were generally healthy. Out of the cases, 41 (38.3%), 57 (54.4%), and 7 (6.7%) had mild, moderate, and severe laryngeal obstruction, respectively. They developed croup after 1-5 days of fever (median 2 days). The majority (90.5%) of COVID-19 children with croup did not have pneumonia, and most of them (64.8%) had decreased eosinophil counts. Additionally, most other blood routine indicators were normal. Five other viral infections (chlamydia pneumoniae, respiratory syncytial virus, adenovirus, coxsackie virus, and mycoplasma pneumoniae) were tested in 51 cases, and all results were negative. All cases recovered from croup after receiving prompt nebulization therapy and/or intravenous drip of hormone. The hospitalization rate was 6.7%. During the 8-month follow-up period, 71 cases experienced repeated fever due to various infections, but only 4 cases (4/105, 3.8%) had repeated croup. Conclusion: Omicron is a risk factor for croup, with most cases presenting mild to moderate laryngeal obstructions. Co-viral infection testing is unnecessary for such cases. The symptoms of Omicron-associated croup may be more severe than croup associated with other viruses; however, unnecessary hospitalizations can be avoided, leading to reduced healthcare expenses.